Claire Verschraegen

Claire Verschraegen, MD


Make an Appointment

Overall Patient Satisfaction Rating

4.8 out of 5




Dutch, English, French, Spanish


I am a professor of medicine and director of the Division of Medical Oncology in the Department of Internal Medicine at The Ohio State University College of Medicine. I also hold the Diane Nye and Michael Rayden Chair in Innovative Cancer Research at Ohio State and serve as associate director for translational research at Ohio State's Comprehensive Cancer Center.

I am a board-certified medical oncologist who specializes in treating patients with rare cancers, including mesothelioma, metastatic melanoma, sarcomas and gynecologic malignancies. Another of my specialties is the study of new anticancer drugs and treatments for solid tumors. My work has been continuously funded for more than 20 years, including grant support for phase I, II and III clinical trials. I have been appointed by the National Cancer Institute (NCI) to serve on many committees, such as the NCI Gynecological Cancer Steering Committee, which approves the federally-sponsored randomized studies for gynecological cancers.

I was recruited to Ohio State in 2017 from the University of Vermont, where I was a professor of medicine, director of Hematology/Oncology, director of the cancer service line and co-director of the University of Vermont Cancer Center. I earned my master's degree and medical degree at the Université Libre de Bruxelles in Belgium and trained at the Institut Jules Bordet in internal medicine/oncology. I then completed a cancer research fellowship at the Stehlin Foundation for Cancer Research and an internal medicine residency training at the University of Houston, followed by a medical oncology fellowship at The University of Texas MD Anderson Cancer Center.

In my 30 years as an academic medical oncologist, much progress has been made in treating some cancers through novel targeted therapies and immunotherapies, a result of the well-planned clinical and translational studies to which I have devoted the greatest part of my professional life. I am privileged to continue this mission at the OSUCCC - James, with which I share a vision of creating a cancer-free world.

Education and Background


Universite Libre De Bruxelles

B-1000 Brussels, Belgium


Universite Libre De Bruxelles

B-1000 Brussels, Belgium

University of Texas Health Sciences Center

Houston, United States

Universite Libre de Bruxelles

Baudour, Belgium


Internal Medicine

Universite Libre De Bruxelles

B-1000 Brussels, Belgium


MD Anderson Cancer Center

Houston, TX


Christus Stehlin Foundation for Cancer Research

Houston, 77025

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Medical Oncology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 11/21/2019, Dr. Verschraegen has reported no relationships with companies or entities.


Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 61 reviews)
4.8 out of 5
Kept you informed about your condition and treatment

4.8/ 5

Amount of time spent with you

4.7/ 5

Concern for your questions and issues

4.8/ 5

Skill and knowledge

4.9/ 5

Overall quality of care

4.9/ 5

Patient Comments (5 total comments)

Reviewed: 10/30/2019

I love Dr. Verschraegen. She is a blessing to us.

Reviewed: 8/2/2019


Reviewed: 5/7/2019

Timely & professional.

Reviewed: 5/6/2019

She is such a wonderful dr. & person just like her team specially Janet Shaffstall!!

Reviewed: 4/30/2019

Super good doctor and staff.


Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.

Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y, Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P, Shi L, Huang W, Shao ZM

Cancer Cell 35


Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen FL, Delord JP, Dowlati A, Kochuparambil ST, Taylor MH, Powderly JD, Vaishampayan UN, Verschraegen C, Grote HJ, von Heydebreck A, Chin K, Gulley JL

JAMA Oncol in press


Related Videos

Addressing Rare Cancers
Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type